APA (7th ed.) Citation

Q, Y., G, C., Y, Y., Z, C., X, A., X, X., . . . H, S. (2026). Conversion therapy using transarterial chemoembolization plus tislelizumab for unresectable hepatocellular carcinoma: Effects on tumor necrosis and anti-tumor immune response. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 28(6), 2208. https://doi.org/10.1007/s12094-025-04159-7

Chicago Style (17th ed.) Citation

Q, Yao, Chen G, Yu Y, Chen Z, An X, Xie X, Wang Q, Chen D, and Sun H. "Conversion Therapy Using Transarterial Chemoembolization Plus Tislelizumab for Unresectable Hepatocellular Carcinoma: Effects on Tumor Necrosis and Anti-tumor Immune Response." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 28, no. 6 (2026): 2208. https://doi.org/10.1007/s12094-025-04159-7.

MLA (9th ed.) Citation

Q, Yao, et al. "Conversion Therapy Using Transarterial Chemoembolization Plus Tislelizumab for Unresectable Hepatocellular Carcinoma: Effects on Tumor Necrosis and Anti-tumor Immune Response." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 28, no. 6, 2026, p. 2208, https://doi.org/10.1007/s12094-025-04159-7.